AbCellera Biologics (ABCL) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 122.4% versus a loss of 9.5%. Over five years, VKTX leads with a +374.9% price change compared with -17.4% for ABCL. AbCellera Biologics is the larger company by market cap ($3.91 billion vs $3.47 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | VKTX |
|---|---|---|
| Share price | $12.07 | $27.31 |
| Market cap | $3.91B | $3.47B |
| 1-day change | -5.96% | -4.33% |
| YTD return | +275.15% | -18.87% |
| 1-year return | +122.36% | -9.50% |
| 5-year return | -17.39% | +374.88% |
| EPS (TTM) | $-0.54 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $0 |
| Revenue growth (YoY) | +160.56% | — |
| Net income (latest FY) | $-146.41M | $-359.64M |
| Operating margin | -288.98% | — |
| Net margin | -194.88% | — |
| 52-week high | $15.02 | $43.15 |
| 52-week low | $2.75 | $25.77 |
| Distance from 52-week high | -19.65% | -36.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +38.42% | +246.86% |
| Average volume | 6.67M | 4.02M |
| Shares outstanding | 324.05M | 127.17M |
| Employees | 562 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed VKTX by 131.9 percentage points over the past year.
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ABCL vs VKTX FAQ
Which is bigger, AbCellera Biologics or Viking Therapeutics?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.91B compared with $3.47B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, ABCL or VKTX?
ABCL returned +122.36% over the past 12 months, compared with -9.50% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.